Sangamo BioSciences | SGMO - Loan Capital


Sangamo BioSciences reported $0 in Loan Capital for its fiscal quarter ending in June of 2022.





Loan Capital Change Date
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Alterity Therapeutics Limited AUD 43.68K 59.53K Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Cipla INR 3.82B 840.2M Mar/2026
Clal Biotechnology ILS 25.96M 18.48M Dec/2023
Compugen USD 0 0 Dec/2024
CSL USD 10.42B 273M Dec/2025
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Grifols EUR 9.95B 722.93M Dec/2025
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
J&J USD 37.34B 183M Jun/2026
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Omeros USD 403.72M 27.2M Jun/2024
Pfizer USD 60.57B 1.08B Mar/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025